Imidazole carboxamides: relationship of lipophilicity to activity against intracerebral murine glioma 26 and preliminary phase II clinical trial of 5-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in primary and secondary brain tumors.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008055:Lipids; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D014226:Triazenes / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007093:Imidazoles; D008055:Lipids; D009588:Nitrogen Mustard Compounds; D014226:Triazenes